Increase in prevalence of HER2-positive cancer due to environmental degradation, rise in adoption of unhealthy lifestyle, and surge in geriatric population is augmenting HER2 antibodies market growth. Overexpression of HER2 protein acts as a biomarker for medical professionals to diagnose cancers of the breast, ovaries, etc. at early stages.
Rise in investment in immunotherapy and other cancer therapeutics is also bolstering the HER2 antibodies market size. Advancements in delivery methods, assisted diagnostics, and improved patient comfort are gaining traction.
Additionally, innovation in manufacturing processes for cancer drugs enables accelerated healing, improved staff productivity, and optimal treatment efficiency. Prominent market players are expanding their footprint in novel regions and merging or acquiring other companies to expand their product portfolio and maintain a stronghold in the competitive landscape.
HER2 (Human Epidermal Growth Factor Receptor 2) antibodies refer to a class of targeted immunotherapies designed specifically to treat cancers caused by HER2-positive genes.
Breast cancer is the most common cancer enabled by the HER2 protein. The protein is expressed overtly in certain cancers. It inhibits the normal functioning of organs and increases cancer cell growth. Anti-HER2 antibody therapeutics are facilitated intravenously, and at times, administered along with chemotherapy and hormonal therapy.
Advantages of HER2-inhibiting immunoglobulins include reduced side effects, minimal damage to healthy tissue, and precise target of cancer cells to enhance patient comfort and accelerate healing.
Recent HER2 antibodies market trends indicate an increase in focus on treatment efficacy, reduced resistance, and scaled applications. Major players are investing in the development of HER2-targeted antibody-drug conjugates, immune checkpoint inhibitors, and bispecific HER2 antibodies for enhanced efficacy.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
HER2 is a protein that promotes the growth of cancer cells in cases when the gene is overexpressed. Prevalence of HER2-positive breast cancer is increasing owing to factors such as unhealthy modern lifestyles, rise in environmental degradation, and drastic increase in the global old age population.
Amplification of the HER2 gene among medical practitioners is a predictive biomarker for several other cancers such as ovary, endometrium, bladder, lung, colon, and head and neck. These growing incidences enhance the need for HER2-positive cancer antibodies and HER2-targeted immunotherapy, thus propelling HER2 antibodies market statistics.
According to the World Health Organization, breast cancer led to the death of over 670,00 people in 2022. Breast cancer was the most common cancer in women in 157 countries out of 185 in 2022. An approximated 1.0% of breast cancer cases are among men
Consistent innovations and investments in gene marking and therapeutics have led to increased efficacy, reliable delivery methods, and improved target mechanism for HER2 antigen-specific antibodies.
Advancements in the anti-HER2 therapy sphere include introduction of novel HER2 antibody engineering approaches, immuno-PET imaging with HER2 antibodies, and companion diagnostics for HER2-positive tumors.
Innovations focused on acceleration of healing, improving patient comfort, and offering personalized treatment options are gaining traction. Furthermore, investments in manufacturing processes in order to optimize costs, production, and staff productivity have been rising.
In 2021, the Cancer Research Institute awarded grants of more than US$ 28.5 Mn for immunotherapy research. More than 120 clinical trials were funded by the institute in 2021 to explore innovative cancer therapy methods. The institute also remarks that around US$ 648.0 Mn is spent to develop a single cancer drug.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America constituted the largest HER2 antibodies market share in 2023. Availability of a robust healthcare infrastructure, rise in biotechnology research, and prevalence of breast cancer in the U.S., Canada, and Mexico are augmenting the market dynamics of the region.
According to the National Breast Cancer Foundation, in the year 2024, approximately 310,720 women and 2,800 men were estimated to be diagnosed with invasive breast cancer in the U.S. Around 43,000 people in the U.S. died due to complications caused by breast cancer in 2023.
As per the latest HER2 Antibodies market forecast, the industry in Europe is set to grow at a steady pace during the period between 2024 and 2034. Access to reliable and subsidized public healthcare and a surge in the geriatric population ate driving market development in the region.
According to data made publicly available by the European Commission, 355,000 women from the EU were diagnosed with breast cancer in 2020, with breast cancer accounting for one-third of all cancer cases among women.
Prominent companies operating in the global HER2 antibodies market are engaged in development of HER2 receptor blockers and precision HER2 targeting agents to cater to the rising cases of breast cancers in the developing world.
Research collaboration with other major players and regional expansion enable companies in the HER2 antibodies industry to reach newer demographics and expand their line of products. Merger & acquisition is also a vital and common strategy that allows companies to maintain a stronghold in the industry.
Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion, Inc., Biocon, and Novus Biologicals are key players operating in this sector.
This HER2 antibodies market report highlights parameters such as company overview, financial overview, product portfolio, business strategies, and business segments of the companies mentioned above.
| Attribute | Detail |
|---|---|
| Market Value in 2023 (Base Year) | US$ 9.0 Bn |
| Market Forecast Value in 2034 | US$ 15.7 Bn |
| Growth Rate (CAGR) | 5.1% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | The qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 9.0 Bn in 2023
It is projected to grow at a CAGR of 5.1% from 2024 to 2034
Increase in prevalence of HER2-positive cancer and advancements in immunotherapy and biotechnology
North America dominated the global landscape in 2023
Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion, Inc., Biocon, and Novus Biologicals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global HER2 Antibodies Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global HER2 Antibodies Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global HER2 Antibodies Market Analysis and Forecast, by Type of Treatment Drugs
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
6.3.1. Trastuzumab
6.3.2. Lapatinib
6.3.3. Ado-trastuzumab Emtansine
6.3.4. Pertuzumab
6.3.5. Everolimus
6.4. Market Attractiveness Analysis, by Type of Treatment Drugs
7. Global HER2 Antibodies Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2020-2034
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America HER2 Antibodies Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings
8.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
8.3.1. Trastuzumab
8.3.2. Lapatinib
8.3.3. Ado-trastuzumab Emtansine
8.3.4. Pertuzumab
8.3.5. Everolimus
8.4. Market Value Forecast, by Country, 2020-2034
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Type of Treatment Drugs
8.5.2. By Country
9. Europe HER2 Antibodies Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
9.3.1. Trastuzumab
9.3.2. Lapatinib
9.3.3. Ado-trastuzumab Emtansine
9.3.4. Pertuzumab
9.3.5. Everolimus
9.4. Market Value Forecast, by Country/Sub-region, 2020-2034
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Type of Treatment Drugs
9.5.2. By Country/Sub-region
10. Asia Pacific HER2 Antibodies Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
10.3.1. Trastuzumab
10.3.2. Lapatinib
10.3.3. Ado-trastuzumab Emtansine
10.3.4. Pertuzumab
10.3.5. Everolimus
10.4. Market Value Forecast, by Country/Sub-region, 2020-2034
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Type of Treatment Drugs
10.5.2. By Country/Sub-region
11. Latin America HER2 Antibodies Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
11.3.1. Trastuzumab
11.3.2. Lapatinib
11.3.3. Ado-trastuzumab Emtansine
11.3.4. Pertuzumab
11.3.5. Everolimus
11.4. Market Value Forecast, by Country/Sub-region, 2020-2034
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Type of Treatment Drugs
11.5.2. By Country/Sub-region
12. Middle East & Africa HER2 Antibodies Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
12.3.1. Trastuzumab
12.3.2. Lapatinib
12.3.3. Ado-trastuzumab Emtansine
12.3.4. Pertuzumab
12.3.5. Everolimus
12.4. Market Value Forecast, by Country/Sub-region, 2020-2034
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Type of Treatment Drugs
12.5.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2023)
13.3. Company Profiles
13.3.1. Novartis AG
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.2. Pfizer, Inc.
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.3. F. Hoffmann-La Roche Ltd.
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.4. Abnova Corporation
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.5. InvivoGen
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.6. Celltrion, Inc.
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Financial Overview
13.3.6.5. Strategic Overview
13.3.7. Biocon
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.8. Novus Biologicals
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
List of Tables
Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
List of Figures
Figure 01: Global HER2 Antibodies Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global HER2 Antibodies Market Revenue (US$ Mn), by Type of Treatment Drugs, 2023
Figure 03: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2023
Figure 04: Global HER2 Antibodies Market Value Share, by Region, 2023
Figure 05: Global HER2 Antibodies Market Value (US$ Mn) Forecast, 2024-2034
Figure 06: Global HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 07: Global HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Figure 08: Global HER2 Antibodies Market Value Share Analysis, by Region, 2023 and 2034
Figure 09: Global HER2 Antibodies Market Attractiveness Analysis, by Region, 2023-2034
Figure 10: North America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 11: North America HER2 Antibodies Market Attractiveness Analysis, by Country, 2024-2034
Figure 12: North America HER2 Antibodies Market Value Share Analysis, by Country, 2023 and 2034
Figure 13: North America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 14: North America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Figure 15: Europe HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 16: Europe HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 17: Europe HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 18: Europe HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 19: Europe HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Figure 20: Asia Pacific HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 21: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 22: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 23: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 24: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Figure 25: Latin America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 26: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 27: Latin America HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 28: Latin America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 29: Latin America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Figure 30: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 31: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 32: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 33: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
Figure 34: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
HER2 Antibodies Market
*86 figures and 60 tables includes